Stimvia Graduates from NYU Stern's Elite Accelerator, Targets U.S. Market with Breakthrough Bladder Therapy

NEW YORK and PRAGUE, May 14, 2025 /PRNewswire/ -- Stimvia, a medtech company from the Czech Republic developing a non-invasive neuromodulation device for the treatment of overactive bladder (OAB), has graduated from the selective Endless Frontier Labs (EFL) program at NYU Stern School of Business. This milestone marks a major step in Stimvia's expansion into the U.S. market, where it is waiting for FDA clearance.

Chosen from over 70,000 science and tech startups across more than 120 countries and regions, Stimvia was one of only 100 companies accepted into the 2024–25 cohort — and one of 55 to successfully complete the nine-month accelerator designed to scale globally impactful ventures.

"This experience gave us sharper insight into what it takes to win in the U.S. market. Over 3,500 clinics still offer patients a 23-year-old technology — we're here to change that. With direct, highly relevant feedback from mentors at EFL, we refined our value proposition to deliver a revolutionary solution. One that simplifies clinic operations and, above all, dramatically improves patient outcomes. We're leaving the program ready to bring real innovation where it's needed most," said Lukas Doskocil, CEO of Stimvia.

Stimvia's flagship device, URIS®, is the first non-invasive closed-loop neuromodulation system designed to treat OAB without surgery or drugs. Using its proprietary eTNM® (peroneal transcutaneous electrical nerve stimulation) method, the device delivers targeted neurostimulation to correct brain-bladder signalling imbalances. Clinical studies show URIS® achieves significant symptom relief in over 90% of patients, with a great safety profile without serious adverse events.

In 2024, the company received MDR (Medical Device Regulation) certification from TÜV SÜD for both its eTNM® and minimally invasive PTNS methods, both based on Stimvia's proprietary technology. This positioned Stimvia as only the third company in the world, and the first in Europe, with MDR approval for both techniques, alongside industry leaders Medtronic and Laborie.

The certification paves the way for reimbursement in global markets and supports Stimvia's plan to access the U.S. neuromodulation market—estimated at nearly $5B annually for OAB alone. The total direct and indirect costs of OAB treatment in the U.S. and Europe exceed $117 billion per year. Yet many patients still lack effective care and face high ongoing costs just to manage their symptoms.

Logo - https://mma.prnewswire.com/media/2036393/3946833/Stimvia_Logo.jpg

SOURCE Stimvia